Celldex Therapeutics, Inc.
ืœื•ื ื’

๐Ÿ’ŠCelldex Therapeutics (CLDX) Analysis: Positive Phase 2 Study

96
Key Highlights:

Positive Phase 2 Study: Celldex Therapeutics revealed positive outcomes from a Phase 2 study of Barzolvolimab, focusing on patients with moderate to severe chronic spontaneous urticaria (CSU) refractory.

Well-Tolerated and Favorable Safety Profile: Barzolvolimab demonstrated general well-tolerance and exhibited a favorable safety profile in the study.

Transformative Potential: CEO Anthony Marucci highlighted the potential transformative role of Barzolvolimab as a treatment option for patients suffering from CSU.

Technical Analysis:

Support Level: The analysis suggests a support level above $35.00-$36.00, indicating a potential floor for price movements.
Upside Target: The upside target is set in the range of $56.00-$58.00, reflecting positive expectations for Celldex Therapeutics.

#CelldexTherapeutics #CLDX #Biopharmaceutical #ClinicalStudy #StockAnalysis #Investing

ื›ืชื‘ ื•ื™ืชื•ืจ

ื”ืžื™ื“ืข ื•ื”ืคืจืกื•ืžื™ื ืื™ื ื ืžื™ื•ืขื“ื™ื ืœื”ื™ื•ืช, ื•ืื™ื ื ืžื”ื•ื•ื™ื, ื™ื™ืขื•ืฅ ืื• ื”ืžืœืฆื” ืคื™ื ื ืกื™ืช, ื”ืฉืงืขืชื™ืช, ืžืกื—ืจื™ืช ืื• ืžื›ืœ ืกื•ื’ ืื—ืจ ื”ืžืกื•ืคืงืช ืื• ืžืื•ืฉืจืช ืขืœ ื™ื“ื™ TradingView. ืงืจื ืขื•ื“ ื‘ึพืชื ืื™ ื”ืฉื™ืžื•ืฉ.